IGF2 related non-islet cell tumour hypoglycaemia in a patient with hepatic sarcoma

A.E Ambrose, E.W Butterly, J.G. Boyle, R.S. Drummond, D Carty, K.A Hughes, G Currie, C Perry
North Glasgow Diabetes and Endocrinology, Glasgow Royal Infirmary, Castle Street, Glasgow, Scotland, G4 0SF

Background
69 year old male
PMHx: epigastric hernia and T2DM
• Initially presented to GP with epigastric and right upper quadrant pain.
• Primary results showed deranged LFTs and CT imaging / biopsy confirmed an inoperable hepatic sarcoma
• A few months later presents to the emergency department with hypoglycaemia and whipple’s triad

Investigations and results
Glucose: 2mmol/L
Insulin: <1.0IU/L
C-peptide: <0.1nmol/L
Short synacthen test: normal
IGF2:IGF1 ratio 14.7 → overproduction of “Big IGF2”

Conclusion
• Results confirm a diagnosis of non-islet cell tumour hypoglycaemia
• IGF-2 binds to target cells like insulin and promotes hypoglycaemia
• There is an overall increase in “big IGF2” and IGF2 in binary complexes; which are more permeable and lead to greater bioavailability further contributing to hypoglycaemia

IGF-2-oma

Discussion
Although rare, the exact incidence of non-islet cell tumours causing hypoglycaemia is unknown and they are often diagnosed late, with hypoglycaemia as the presenting symptom in many cases.2

Treatment options are limited, however if surgical resection is possible, hypoglycaemia can be fully resolved. Unfortunately for this patient, the tumour was inoperable due to size and location.

Management consisted of steroids at supraphysiological dose and regular carbohydrate intake. Despite this, he required multiple hospital admissions for hypoglycaemia.

Other treatment options include recombinant growth hormone, which increases gluconeogenesis, ALS and IGFBP3; however this would also increase tumour growth in this case. Glucagon and diazoxide have also been used, although evidence is limited.

References

Figure 1: Effects of “big IGF-2” on target cells

Figure 2: IGF-2 produced by tumours has increased permeability and bioavailability to tissues. Normally, 80% of IGF-2 is bound in the ternary complex, in IGF-2 secreting tumours, 80% is bound in the binary complex.